View More Recent Stories
-
InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients
-
InspireMD (NSPR) Announces Senior Leadership Changes
-
InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives
-
InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23
-
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
-
InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
-
InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update
-
InspireMD (NSPR) Announces $113.6M Private Placement
-
InspireMD Announces Private Placement of Up to $113.6 Million
-
InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform
-
InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
